Phase 4
N=142
The Use of Bupivacaine and Ropivacaine for Sciatic Nerve Block
The Duration of Motor Block May Vary Between 12-36 Hrs
Bottom Line
View on ClinicalTrials.gov: NCT01272921 ↗Enrolled (actual)
142
Serious AEs
0.0%
Results posted
Mar 2014
Primary outcome: Primary: Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL — 10; 7; 21; 15 Hours — p=0.05
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Bupivacaine (Drug); Ropivacaine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- Aug 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Motor and Sensory Block of the Sciatic With 0.5% Bupivacaine and Ropivacaine After Ultrasound-guided Nerve-stimulator-Assisted Needle Positioning Beneath the CIEL |
10; 7; 21; 15; 9; 8 | 0.05 |
| SECONDARY Cumulative Probabilities for Needle Positioning Above and Below CIEL. |
0.52; 0.19 | <0.001 sig |
Summary
The duration of motor block for infragluteal parabiceps sciatic nerve block following total knee replacement may vary between 12-36 hrs depending on the amount of local anesthetic given.
Eligibility Criteria
Inclusion Criteria
- Adult patients (>18 years of age) who are undergoing elective total knee arthroplasty will be included in the study.
Exclusion Criteria
- Exclusion criteria for the study are patient refusal to be included in the study, contraindications to regional anesthesia, history of allergy to amide local anesthetics, the presence of a progressive neurological deficit, the presence of coagulopathy or infection, or pregnancy
Data sourced from ClinicalTrials.gov (NCT01272921). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.